Podcasts about nih

Your brain doesn't just run on chemistry. It runs on time.Every day your body broadcasts signals through sleep timing, light exposure, body temperature, hormones, and circadian rhythms—yet most people ignore these patterns while chasing pills, supplements, and productivity hacks.In this episode of the Crackin' Backs Podcast, we sit down with Benjamin Smarr to explore a new frontier of human biology: how time-series biology and wearable data may unlock powerful, non-drug ways to improve brain health, mood, and performance.Dr. Smarr's research looks at the body not as a snapshot—but as a movie, where continuous biological signals reveal patterns that traditional medicine often misses.In this episode, we explore:Why “normal” is a misleading concept in human biologyHow circadian rhythms and sleep timing shape mental performance and moodWhat wearable devices can reveal about your hidden biological patternsWhy body temperature rhythms may be linked to depression and mental healthThe overlooked role of light timing, temperature regulation, and daily rhythmsHow “social time” vs biological time affects cognition, sleep, and productivityWhere self-tracking and wearable data help—and where they can backfireWhether the future of medicine could include “time prescriptions” instead of drugsThis conversation reframes how we think about health, performance, and mental well-being—not as something fixed, but as something that shifts with how we live in time.If you're interested in sleep science, circadian biology, wearables, mental performance, precision health, and the future of non-drug brain optimization, this episode will challenge how you think about your own body.About Dr. Benjamin SmarrBenjamin Smarr is an Associate Professor of Bioengineering and Data Science at the University of California, San Diego (UCSD). He earned his PhD in Neurobiology from the University of Washington, and later served as an NIH fellow at UC Berkeley in Psychology.His research focuses on biological rhythms, neuroendocrinology, wearable health data, and HealthAI, developing technologies that improve precision medicine while reducing algorithmic bias for diverse populations.The Smarr Lab works at the intersection of women's health, aging, circadian biology, and data science, aiming to accelerate the future of personalized healthcare and population-level health insights.Dr. Smarr's work and insights have been featured in global media outlets including NPR, BBC, Forbes, and many others. He is also a strong advocate for science communication and community empowerment in discovery and health innovation.Learn more about his research and work HERE:  We are two sports chiropractors, seeking knowledge from some of the best resources in the world of health. From our perspective, health is more than just “Crackin Backs” but a deep dive into physical, mental, and nutritional well-being philosophies. Join us as we talk to some of the greatest minds and discover some of the most incredible gems you can use to maintain a higher level of health. Crackin Backs Podcast

What is in the This Week in Science Podcast? This Week: European Ignobel, NIH, Tamper-Free Viruses, Origami Vaccines, Garbled Messages, Brain Cell Centers, Gnawing Need, and Much More Science to Gnaw on! Become a Patron! Check out the full unedited episode of our science podcast on YouTube or Twitch. And remember that you can find TWIS […] The post 11 March, 2026 – Episode 1051 – Gnaw On This For a Bit appeared first on This Week in Science - The Kickass Science Podcast.

When discussing Gen Z and "ghosting," the term often refers to young adults abruptly cutting communication in relationships or at work. But research shows this group is now ghosting alcohol. According to the data, Gen Z and millennials are turning away from drinking and traditional nights out. Being "sober curious" is becoming more popular. But Alcohol Use Disorder (AUD) remains a health concern in this country. The NIH reports that nearly 28 million Americans ages 12 and older struggled with AUD from 2024-2025. A new play at Blackfriars Theatre called "The White Chip" tells the story of one man's struggle living with addiction and his path to recovery. Our guests tell us what we can learn from the play — and from lived experience. In studio: Matt Ames, director of "The White Chip" Katelyn Machnica, Actor #1 in "The White Chip" Kara Izzo, peer support program manager at ROCovery Netzi Montano, FNP-C, nurse practitioner at Delphi Rise ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

Howie and Harlan are joined by Yale School of Medicine surgical oncologist Kevin Billingsley, who discusses how robotics and advanced imaging are reshaping what it means to be a surgeon and offers guidance for those facing a cancer diagnosis. Harlan reports on a company testing AI-based prescription renewals and raises concerns about safety and oversight; Howie reflects on new survey data showing declining public trust in health institutions. Show notes: Unsupervised AI Health & Veritas Episode 207: Robert Wachter: AI Is Already Remaking Healthcare "Vinod Khosla: Machines will replace 80 percent of doctors" Doctronic AI Regulatory Mitigation Agreement "AI could soon renew prescriptions without clinician help. Should the FDA make sure it's safe?" "Exclusive: Researchers trick a bot that prescribes meds" "Don't trust this $4 solution for getting a prescription" "CVS Health And Google Launch AI Business To 'Personalize Healthcare'" Health & Veritas Episode 206: Mary-Ann Etiebet: Confronting Preventable Disease Harlan discusses ARPA-H. Kevin Billingsley Laparoscopy Robotic Surgery "History of robotic surgery: from AESOP and ZEUS to da Vinci" "Personal Best" Atul Gawande compares surgeons to athletes.  "Future of Surgical Training Will Include Major Shift in Education Model" "Will your next surgeon be a robot? Autonomy and AI in robotic surgery" "Dying Words" Jerome Groopman on the relationship between oncologists and patients. "Teamwork in Healthcare: Key Discoveries Enabling Safer, High-Quality Care" Smoking and Cancer Benefits of Physical Activity Physical Activity and Cancer Health & Veritas: Melinda Irwin: Can Nutrition and Exercise Improve Cancer Outcomes? "What Alcohol Does to the Body" Who do you trust? "Stark Divide: Americans More Confident in Career Scientists at U.S. Health Agencies Than Leaders" "Poll: Americans increasingly trust career scientists, not leaders, at CDC, NIH, and FDA" Your Local Epidemiologist: "Top 5 questions about school vaccination requirements" Health & Veritas Katelyn Jetelina: A Visit from Your Local Epidemiologist" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Newly-minted Nobel laureate Fred Ramsdell joins Claudia to discuss his groundbreaking work on regulatory T cells, which act as the immune system's natural "brakes." His research aims to "reset" the immune system to cure autoimmune diseases (like rheumatoid arthritis and MS) moving beyond mere symptom management. Fred reflects on his new role as a science advocate, addressing the crisis of public trust in science and the need for greater diversity in biomedical research.During this conversation, recorded at the UC Berkeley/JP Morgan Healthcare Conference in Taipei, Claudia and Fred discuss:How Fred missed the Nobel Prize call while off-grid campingHis shifting goals in retirement post Nobel winWhy he chose biotech: collaboration, speed, and being "wrong fast"The deeper threat to science: funding vs. trust, and his surprise in SwedenFred says he's excited to see what other advances are possible in what he calls “the early innings” of scientific discovery:“As humans, we're really good at solving technological problems. If we know what the problem is, historically, we're pretty good at figuring out an answer. [We're] pretty confident now that we know the problem in peripheral tolerance, that is the breakdown of our immune system recognizing our own tissues. Now we know what at least part of that problem is, we'll be able to engineer our way into a solution.”Relevant LinksSee more about Fred's Nobel win and read the UCLA press releaseFred's Nobel prize lectureSee Fred and his co-laureates accept their prizeRead more about Fred's 2025 co-laureates Mary E. Brunkow and Shimon SakaguchiAbout Our GuestFred Ramsdell, PhD, is a veteran biotechnology leader in immunology with nearly three decades of experience and was named a winner of the 2025 Nobel Prize in Physiology or Medicine. A co-founder of Sonoma Biotherapeutics, Dr. Ramsdell was the former Chief Scientific Officer (CSO) and current Scientific Advisory Board Chair of the Company.Dr. Ramsdell earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a bachelor's degree in biochemistry and cell biology from the University of California, San Diego. Following a fellowship at the NIH, Dr. Ramsdell joined Immunex studying T cell activation and tolerance, with a focus on gene discovery and functional characterization. He later joined Darwin Molecular (which was later acquired by Celltech R&D) to establish the immunology program. Amongst other programs, he led the team that discovered and characterized FoxP3, a gene critical to the function of regulatory T cells. Dr. Ramsdell joined ZymoGenetics in 2004, where he led teams studying novel proteins with potential regulatory activity in lymphoid cells. In 2008, Novo Nordisk brought on Dr. Ramsdell to help establish the company's new Inflammation Research Center in Seattle and lead the Immunobiology group. Prior to SonomaBio, Dr. Ramsdell was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped to build and advance multiple research programs from the inception of the Institute.SourceConnect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter @claudiawilliams and LinkedInSubscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes!

The Space Show Presents Trisha Epp. Sunday, 2-22-26Quick Summary:The Space Show hosted Trisha Epp, Director of Innovation at Freelancer.com, to discuss NASA's open innovation challenges and Freelancer's role in facilitating these competitions. Trisha explained how Freelancer works with NASA's Tournament Lab to run innovation challenges that attract solutions from around the world, with prize money awarded for successful ideas. The discussion covered the differences between Freelancer's approach and traditional government RFP processes, highlighting cost savings and broader participation as key advantages. Trisha shared that Freelancer has helped NASA achieve significant cost savings through their innovation challenges, with approximately 30-50 winners per year. The conversation also touched on the use of AI in submissions, ethical concerns around AI art, and potential expansion of these innovation methods beyond NASA to other industries.Detailed SummaryTrisha Epp, an innovation strategist based in Vancouver, discussed her work leading open innovation challenges for NASA, NIH, and other institutions through Freelancer.com's NASA Tournament Lab. She explained that Freelancer helps find engineers and carry out innovative projects, particularly those that fit within NASA's challenge section. The discussion also touched on potential future projects in space, such as 3D printing organs in space while David shared his personal interest in advancements in knee replacement technology derived from space tech.Trisha explained her role as Director of Innovation at Freelancer, where they work with NASA through the NASA Tournament Lab and Center of Excellence for Collaborative Innovation to explore open innovation solutions. She detailed how Freelancer facilitates innovation challenges where participants compete to solve specific NASA problems, with successful ideas being licensed to NASA and potentially leading to further development. Trisha mentioned that Freelancer is one of 25 vendors on NASA's Open Innovation Services 3 contract, specializing in finding global solutions, and shared a success story about a Norwegian engineer whose work on software testing for the Orion spacecraft will be used in the Artemis II mission.Trisha explained how NASA's Center of Excellence for Collaborative Innovation facilitates faster innovation through open competitions compared to traditional procurement processes. She detailed how Freelancer's platform helps connect solvers with NASA challenges, with typical prize pools of $100,000 and above, and described the evaluation process conducted by NASA engineers. Trisha also highlighted the diversity of participants, ranging from university students to professionals from various fields, and the motivation factors driving their involvement.Trisha discussed the challenges of treating rare diseases and the importance of developing effective delivery methods for treatments. She mentioned NASA's upcoming program to analyze data from astronauts on the Artemis II mission and a competition for innovative methodologies. David inquired about solutions for unidentified aerial phenomena (UAP), but Trisha had not seen any official documentation on the topic. Trisha also shared her excitement about a global competition for designing a zero-gravity indicator for the Artemis II mission, which is still awaiting results. She expressed disappointment over NASA's decision not to publish winning designs from an art challenge due to the use of AI art, which she hoped would be addressed in the future.Trisha and David discussed the ethical concerns around AI, particularly regarding the use of artists' work without consent for training AI models. David shared that their website, thespacehow.com, was targeted by AI crawlers, leading to data loss and the implementation of Cloudflare for protection. Trisha mentioned her work on a program with ex-Microsoft AI professionals and the Department of Energy to develop a healthy human-AI interaction index. The discussion concluded with Trisha expressing interest in expanding their work beyond NASA to other industries, leveraging a methodology developed with NASA to tackle complex problems.Trisha explained that their innovation challenge methodology offers significant cost savings compared to traditional RFP processes, with only 1-10% of prize money paid out when solutions are not found, and highlighted their success in attracting new audiences and finding unexpected solutions. When discussing how to evaluate and compare different methodologies like NIAC's, Trisha suggested looking at metrics such as outreach and the number of people reached, while Philip noted that NIAC aims to find transformative ideas that could disrupt existing ways of doing things, though he questioned whether their published results truly meet this goal.Toward the end of the program we discussed NASA's grant program structure and competition model, where successful proposals receive direct awards rather than requiring deliverables. Trisha explained that NASA typically awards 30-50 winners per year across various programs, with winners receiving funds to scale up their work without strings attached. The participants explored the concept of independent oversight for proposal selection processes and discussed upcoming challenges, with Trisha sharing resources including NASA's COECI opportunities website.Special thanks to our sponsors:American Institute of Aeronautics and Astronautics, Helix Space in Luxembourg, Celestis Memorial Spaceflights, Astrox Corporation, Dr. Haym Benaroya of Rutgers University, The Space Settlement Progress Blog by John Jossy, The Atlantis Project, and Artless EntertainmentOur Toll Free Line for Live Broadcasts: 1-866-687-7223 (Not in service at this time)For real time program participation, email Dr. Space at: drspace@thespaceshow.com for instructions and access.The Space Show is a non-profit 501C3 through its parent, One Giant Leap Foundation, Inc. To donate via Pay Pal, use:To donate with Zelle, use the email address: david@onegiantleapfoundation.org.If you prefer donating with a check, please make the check payable to One Giant Leap Foundation and mail to:One Giant Leap Foundation, 11035 Lavender Hill Drive Ste. 160-306 Las Vegas, NV 89135Upcoming Programs:Broadcast 4514 Zoom Jim Muncy | Tuesday 10 Mar 2026 600PM PTGuests: James A. M. MuncyZoom: Jim Muncy on Artemis, policy and much moreBroadcast 4515: Hotel Mars with Dr.Pieter.van Dokkum, Yale Univ. | Wednesday 11 Mar 2026 930AM PTGuests: John Batchelor, Dr. David Livingston, Dr. Pieter van DokkumHotel Mars on the subject of runaway black holesFriday, March 13: No program today | Friday 13 Mar 2026 930AM PTGuests: Dr. David LivingstonNo program todayBroadcast 4516 Zoom: Phil Swan | Sunday 15 Mar 2026 1200PM PTGuests: Phil SwanZoom: Phil Swan discusses launching orbital data centers from the MoonSpace Show weekly schedule pending. See Upcoming Show Menu on the right side of our home page, www.thespaceshow.com. The weekly newsletter will be posted on Substack when completed. Get full access to The Space Show-One Giant Leap Foundation at doctorspace.substack.com/subscribe

Can you reverse fatty liver disease with a ketogenic diet?Fatty liver disease is now one of the fastest-growing liver conditions in the world, affecting roughly 30% of adults and an increasing number of children. And in many cases, it's driven by metabolic dysfunction and insulin resistance.In this conversation, Dr. Bret Scher speaks with Dr. Amy Goss (University of Alabama at Birmingham) and Dr. Karen Jerome-Zapadka (Trajectory Health Partners) about the growing epidemic of metabolic dysfunction–associated steatotic liver disease (MASLD) and why carbohydrate restriction and ketogenic nutrition may be powerful tools for addressing it.In this interview, you'll learn:What MASLD (formerly NAFLD) is and why it's becoming so commonHow insulin resistance and excess carbohydrates contribute to fatty liverNew research showing how carbohydrate restriction can reduce liver fatWhy ketogenic and low-carb diets may improve liver metabolism beyond weight lossThe clinical experience of reversing fatty liver through metabolic therapyWhy lifestyle approaches often receive less attention than medicationsDr. Amy Goss and her team at the University of Alabama at Birmingham are currently conducting a large NIH-funded clinical trial investigating how carbohydrate restriction affects liver fat and insulin sensitivity in adolescents with fatty liver disease.At the same time, Dr. Karen Jerome-Zapadka is applying these metabolic principles in clinical practice at Trajectory Health Partners, helping patients reverse steatotic liver disease through carbohydrate reduction and comprehensive metabolic care. Together, their research and real-world clinical experience are helping advance a deeper understanding of how targeting metabolic dysfunction may transform the way fatty liver disease is treated.Curious about the safety of ketogenic therapy? Visit our Is Keto Safe topic page to see all of our top content on the topic: https://www.metabolicmind.org/resources/topics/is-keto-safe/

Today on the Federal Drive with Terry Gerton U.S. organizations should prepare for potential retaliation in the cyber domain as tensions with Iran escalate NIH sets up camp near one of the worst environmental disasters ever A stalled DHS funding fight at home and rising tensions abroad are pushing Congress into another week of high‑stakes maneuveringSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week inside the courtroom, science took center stage — and the stakes were higher than ever.Dr. Kara Bagot, a psychiatrist and neuroscientist who helped develop the NIH's landmark ABCD brain study, spent five days on the stand. She testified that to a reasonable degree of medical certainty, Kaley developed social media addiction — and that YouTube acted as the “gateway,” beginning at just six years old. She walked the jury through the platform features that fuel compulsive use: infinite scroll, autoplay, algorithms, notifications, likes, filters, Shorts, Reels, and the lack of meaningful age verification.Under intense cross-examination from Meta and YouTube's attorneys, Dr. Bagot held her ground — insisting on context over yes-or-no soundbites. Jurors watched closely. When she was finally excused, there as a quiet applause.Then came former Meta safety executive and whistleblower Arturo Bejar. He testified that by 2019, Meta researchers had identified addiction as a serious issue — but leadership discouraged even using the word, replacing it with “problematic use.” He described internal knowledge of harmful design choices, ineffective safety tools, and what he called “dark patterns,” including the infamous “blue button” that discouraged user reporting.Arturo also testified that age verification is not technically difficult — and that Meta could remove millions of under-13 users if it chose to.Next up was child safety expert and mom, Brooke Istook. Brooke powerfully described the generational tech gap, Instagram's growth team promoting FINSTAs, misleading safety promises, and the no-win position families face trying to supervise platforms designed to outmaneuver them.By week's end, the Plaintiffs rested their case and the Defense began calling witnesses in the form of video depositions.Meanwhile, outside this courtroom, the pressure is mounting. Big tech lobbyists have infiltrated important online safety legislation and 33 new families across 19 states have joined the consolidated JCCP litigation, with Roblox newly added to the complaints.Thousands of families. Dozens of states. And now jurors — everyday people — watching some of the richest companies in the world fight a single family over what caused a young girl's harm.These are the tobacco trials of our generation.We're inside the courtroom translating it all in real time — joined this week by Christine Almadjian, legislative consultant and courtroom observer, and Lennon Torres of Heat Initiative — bringing you the moments that mattered, the legal context behind the strategy, and what it means for families everywhere.Because this fight isn't abstract.It's about the apps in our kids' pockets.It's about truth, justice and accountability.And it's about whether these companies will finally be forced to change.We stand with families.The Heat is On...Big Tech on Trial is an investigative mini-series by Scrolling 2 Death, in partnership with Heat Initiative.Video Editing expertly provided by Jacob Meade.

This week we listen in to a wonderful presentation that was delivered at the CHOP 2026 annual conference which was held in Phoenix, AZ. In this week's lecture we hear Dr. Gail Pearson of the NHLBI and NIH deliver her thoughts about the future of congenital heart research. Where does this master of research believe the next discoveries are going to arise from? What are the lessons we have learned from the PHN research endeavors over the past 25 years? Dr. Pearson offers her thoughts in this wonderful presentation which was the 24th Annual William J. Rashking Memorial Lecture at this conference. This presentation was delivered on 2.28.26.

In part two of the series, Dr. Andy Southerland and Dr. Seemant Chaturvedi break down key takeaways from the OCEANIC‑STROKE trial.  Show citation:  Read more about the OCEANIC-STROKE trial.  Show transcript:  Dr. Andy Southerland:  Hello everyone. This is Andy Southerland from the University of Virginia. For today's Neurology Minute, I've just been speaking with my colleague, Seemant Chaturvedi from the University of Maryland, about exciting trials presented at this year's 2026 International Stroke Conference from the American Heart Association, American Stroke Association. And the one we want to discuss for today's Neurology Minute in brief was the OCEANIC-STROKE trial. This was a very large international trial looking at the use of a novel antithrombotic agent, a Factor XI inhibitor, compared to placebo as an adjunct to our traditional antiplatelet therapies for secondary stroke prevention. And it was received with quite a bit of excitement. So Seemant, tell us in brief, what did we learn from OCEANIC-STROKE? Dr. Seemant Chaturvedi:  One new class of agents, which is being tested are the Factor XIa inhibitors. And this has a unique mechanism of action, and it's believed that it can reduce thrombotic events without causing an increase in bleeding, which would be truly a major breakthrough. And so in OCEANIC-STROKE, over 12,000 patients were enrolled with either stroke or high-risk TIA within 72 hours of the last event. And the trial found that patients who had fairly mild strokes with a median NIH score of two, that when you add the asundexian 50 milligrams per day on top of either dual antiplatelet or single antiplatelet therapy, that there was an improved outcome and reduction in stroke with asundexian. There was a 2.2% absolute reduction in ischemic stroke, 26% in relative terms. Stroke, MI, and vascular death was also reduced with asundexian, as was disabling stroke. An exciting finding was that major bleeding was not increased with asundexian. And so this confirmed the preclinical hypothesis. And so I think this was a significant result in terms of reducing recurrent ischemic stroke without increasing bleeding. And so I think we eagerly await the full publication, and I think it could be applicable to many of the patients that we see in our clinical practice. Dr. Andy Southerland:  So asundexian, folks, you'll hear more about this as the drug hopefully comes on the market and we see the full primary publication of this OCEANIC-STROKE trial, but exciting nonetheless to have a possible new treatment to help us reduce the risk of recurrent stroke for our patients. So Seemant, thanks so much again for joining us for today's Neurology Minute. And I encourage all of our listeners, as always, to listen to the full podcast interview ain The Neurology Podcast. Seemant, thanks for joining us. Dr. Seemant Chaturvedi:  My pleasure.  

Today's guest is Jason Luoma, PhD. Jason is a clinical psychologist, researcher, entrepreneur, and psychotherapy trainer based in Portland, Oregon. For over two decades, Jason's research has focused on shame, stigma, and the interpersonal functions of emotion, with more recent work centered on psychedelic science. He served as Principal Investigator on one of the first MDMA-assisted psychotherapy trials in the Pacific Northwest and has contributed to multiple NIH-funded clinical trials in roles including co-investigator, consultant, therapist, and trainer.Jason is co-author of the bestselling ACT text Learning Acceptance and Commitment Therapy and Values in Therapy, and is currently writing a book on psychedelic-assisted therapy for Guilford Press. A longtime leader in the ACT community, he is a peer-reviewed ACT trainer, former president of the Association for Contextual Behavioral Science, and co-founder of several innovative organizations, including the Portland Psychotherapy Clinic, Research, & Training Center and the Portland Institute for Psychedelic Science.He also hosts The Research Matters Podcast, where he interviews leading researchers about what makes their work impactful and effective.Some of the topics we explore in this episode include:-His early development in Steve Hayes' lab-The evolution of ACT and contextual behavioral science-The need for more experiential learning for clinicians -psychedelics and their application for healing-Hopes for the future of psychedelic assisted therapy —————————————————————————Jason's Website: https://jasonluoma.com/—————————————————————————Thank you all for checking out the episode! Here are some ways to help support Mentally Flexible:You can help cover some of the costs of running the podcast by donating a cup of coffee! www.buymeacoffee.com/mentallyflexiblePlease subscribe and leave a review on Apple Podcasts. It only takes 30 seconds and plays an important role in being able to get new guests.https://podcasts.apple.com/us/podcast/mentally-flexible/id1539933988Follow the show on Instagram: https://www.instagram.com/mentallyflexible/Check out my song “Glimpse at Truth” that you hear in the intro/outro of every episode: https://tomparkes.bandcamp.com/track/glimpse-at-truthCheck out my new album, Holding Space! https://open.spotify.com/album/0iOcjZQhmAhYtjjq3CTpwQ?si=nemiLnELTsGGExjfy8B6iw

In this episode, host Ross welcomes back Dr. Jay Bhattacharya, Director of the National Institutes of Health and interim Director of the Centers for Disease Control and Prevention. They dive into the importance of vaccination, particularly in the context of the current measles outbreak. Dr. Bhattacharya shares the official CDC position on childhood vaccines and the risks associated with not vaccinating. They also discuss the challenges of working in government, including navigating bureaucracy and building coalitions. The conversation touches on the role of the NIH and CDC in public health, and how their missions are often misunderstood.See omnystudio.com/listener for privacy information.

In part on of this series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss two trials highlighted at the 2026 International Stroke Conference.  Show citation:  Read more about the CHOICE-2 trial.  Show transcript:  Dr. Andy Southerland: Hello everyone. This is Andy Southerland. And for this week's Neurology Minute, I have just been speaking once again with my colleague, Seemant Chaturvedi, about his impressions from this year's 2026 American Heart Association, American Stroke Association International Stroke Conference. We've discussed a number of the very exciting pivotal trials presented at this year's meeting that occurred just a couple of weeks ago. But for the minute today, we want to just highlight two that were represented as late breaking trials in the world of acute stroke treatment. And the first was OPTION, which was a trial looking at extended window thrombolysis patients between four and a half and 24 hours. And the second was in the use of thrombolysis as an adjunct local treatment in patients receiving thrombectomy. So Seemant, to the best of your ability in our brief snippet today, what were the main highlights from these studies? Dr. Seemant Chaturvedi: In the OPTION trial, 570 patients were enrolled from China, and these were patients in the four and a half to 24 hour window with no evidence of large vessel occlusion. And they had a mismatch present at baseline imaging, median NIH score was seven. And when the tenecteplase was administered in this select group of patients, there was improvement in the excellent outcome of about 44% with tenecteplase and 34% with placebo. And there was a slight increase in hemorrhage of about 3%, but no increase in mortality. The second trial, CHOICE-2, also looked at thrombolysis, but it looked at local intraarterial thrombolysis following thrombectomy. And they enrolled patients with a median NIH score of 15 and the patients were enrolled from Spain and they gave a local TPA versus placebo following successful thrombectomy. And they also reported improved outcomes with about 57.5 having an excellent outcome with intraarterial TPA compared to 43% with placebo. There was slightly increased mortality in the TPA group, but this didn't seem to be explained by intracerebral hemorrhage. And so I think both of these were very intriguing and they add some complexity to acute stroke treatment. And so primary stroke centers and comprehensive stroke centers need to discuss the results with their teams and see if they want to embrace these treatment options. Dr. Andy Southerland: Fantastic, Seemant. So bottom line is thrombolysis is much more than it used to be in that very narrow time window and that very narrow indication. There are now patients who may benefit in that extended time window, and it's also being shown to have benefit in cases in which we get incomplete reperfusion with our traditional mechanical thrombectomy. So take that and run with it. Hopefully we can apply it to our stroke systems of care and help patients. Thank you again, Seemant for being with us on today's Neurology Minute. Seek out the full interview and also the primary publications as well.  

Glenn Sturm shares his experience of being diagnosed with aggressive T-cell lymphoma in 2009, initially dismissing the news as a prank. He describes his approach to handling the diagnosis by conducting research and assembling a team of medical professionals, eventually connecting with Dr. Foss at Yale, a leading expert in his type of cancer. Glenn emphasizes his background in building teams and his natural inclination to collaborate, which he applied to his cancer treatment strategy. Glenn shares his personal journey with cancer, highlighting how defining himself through helping others has improved his well-being. He discusses his ongoing chemotherapy and his work on multiple books, including a novel and a book about a multifaceted approach to cancer treatment. Glenn also mentions his commitment to donating proceeds from his astrophotography and photography to Children's Health, emphasizing the importance of teamwork and communication in his cancer treatment. Key takeaways Glenn Sturm has been living with T-cell lymphoma for 18 years, receiving continuous chemotherapy treatment Multidisciplinary cancer care approaches can reduce mortality rates by 18-90% compared to siloed approaches Glenn advocates for building a comprehensive healthcare team that includes specialists beyond oncologists Glenn's upcoming book "More Than Hope" focuses on integrated cancer care approaches Glenn emphasizes the importance of celebrating life and helping others despite health challenges NIH studies show that multidisciplinary approaches to cancer treatment significantly improve survival rates To find out more about Glenn's work visit glennsturm.com Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

This National Kidney Month, we celebrate the unsung heroes of the human body. Kidneys do so much more than filter blood (they've been described as the body's “cleaning crew” and “inventory managers”), so keeping them functioning well is vital to our overall health. Joining us to sing the praises of kidneys – and learn how to keep them healthy – is Dr. Kristin Meliambro, an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. Dr. Meliambro walks us through the many essential jobs kidneys do for us and breaks down the various causes of kidney disease. She also shares practical lifestyle habits that support long-term kidney health.   The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at 1199SEIUBenefits.org/food-as-medicine. For additional information and support, visit the National Kidney Foundation website, at Kidney.org, and the American Association of Kidney Patients, at www.aakp.org. For information about kidney donation, visit the Nation Kidney Registry page at KidneyRegistry.com Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents.   Guest Bio Kristin Meliambro, MD, is an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. She earned her medical degree from the Icahn School of Medicine at Mount Sinai, and she completed both her internal medicine residency and clinical and research nephrology fellowships at the Mount Sinai Hospital. In addition to treating patients with a wide range of kidney diseases in diverse clinical settings, Dr. Meliambro is an NIH-funded physician-investigator who conducts basic and translational research with a focus on mechanisms of kidney podocyte injury and novel disease therapies. She is the co-Director of the Nephrology Division's Renal Biorepository, which banks biological specimens and collects clinical data from patients starting at the time of kidney biopsy and continuing longitudinally. She also actively participates as a PI and Co-Investigator in clinical trials testing novel agents for glomerular diseases. Dr. Meliambro also has a strong record of research mentorship of Associate Researchers and graduate/medical students in her lab, the majority of whom have been women and from under-represented minorities in science and medicine. Dr. Meliambro sees patients with a variety of kidney diseases, and she has a particular clinical interest in glomerular diseases. Her clinical responsibilities include the care of outpatients at the Mount Sinai Doctors nephrology practice, hemodialysis patients at Central Park Dialysis Center and inpatients at the Mount Sinai Hospital, where she also teaches and supervises nephrology fellows on the inpatient nephrology services.

Doug Crawford, Ph.D., is the founder of MBC BioLabs and also a Managing General Partner of Mission BioCapital. Doug's goal is to help entrepreneurial scientists create successful startups. His dream is that every entrepreneurial scientist with a dream be given a chance.  Since its founding, this program has helped launch 500 companies and helped raise over $20 billion in capital. Robert Blazej, Ph.D., is a Partner at Mission BioCapital and Director at MBC BioLabs. He is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that microdroplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. This conversation can be considered as the 2026 State of the Union for early-stage biotech. The biotech landscape has shifted drastically- we moved from the grow-at-all-costs zero-interest-rate era to a world of tight capital and high discipline. The undisputed capital of biotech in Boston is facing unprecedented lab vacancies. AI is dominating every pitch deck. And China has rapidly evolved from a manufacturing hub into a multi-billion-dollar discovery engine.   Shownotes https://mbcbiolabs.com/; https://www.missionbaycapital.com/ How did Doug and Robert meet? Progress Mission Biolabs made in the past 4 years God's eye view of the biotech startup world- What is being built? DNA of the founders: repeat founders on the rise Capital restraints and advances in science made the current period the best time to launch biotech startups. With the advent of AI, we should not be making knowable mistakes Companies are using AI to jumpstart what they are going to work on Discovery costs are the overall cost of drug discovery- So, don't get too excited! How to address reduction in NIH non-dilutive funding ⅓ of startups in incubators are serial entrepreneurs; ⅓ are mid-career scientists from established companies  Comparing Boston and the Bay area biotech ecosystems 73% of pharma's revenues are from discoveries sourced externally Alternate models: Arena bioworks, Arc Institute, Chan Zuckerberg institute Book recommendation - Thinking in Bets Actual impact of AI at Mission Biolabs Where Ai might have the most impact- healthcare delivery? China affairs: Regulatory changes, investments, return of talent European biotech affairs

In this episode, David Watumull breaks down the science behind astaxanthin — a powerful carotenoid antioxidant backed by over 4,000 peer-reviewed papers and 100+ human clinical trials — and explains why it may be one of the most underappreciated longevity compounds available today. The conversation explores how astaxanthin anchors across cellular membranes to protect mitochondria from oxidative stress, reduce chronic inflammation ("inflammaging"), support cardiovascular health by lowering oxidized LDL and CRP, and cross the blood-brain barrier to enhance cognitive function and neuroprotection. They also discuss its role in energy production, endurance performance, healthy aging, and a landmark NIH lifespan study showing a 12% extension in mammals. Ultimately, the episode reframes longevity not as chasing stimulants or shortcuts, but as protecting cellular integrity so the body can function the way it was designed to — for longer and at a higher level. ----- 00:00 – The Longevity Molecule You've Never Heard Of 02:45 – What Is Astaxanthin? 07:30 – How It Protects Your Cell Membranes 13:40 – Free Radicals & Oxidative Stress Explained 25:50 – Brain Health, Neuroplasticity & Mitochondria 29:40 – Cardiovascular Disease & Oxidized LDL 34:05 – Alzheimer's, MCI & Neuroprotection 43:00 – Energy Production & Mitochondrial Function 58:40 – Inflammaging & Longevity Pathways 1:03:40 – NIH Study: 12% Lifespan Extension 1:09:00 – Athletic Performance & Endurance 1:15:00 – Dosing, Absorption & Bioavailability 1:26:00 – Can Antioxidants Become Harmful? 1:30:00 – Why Isn't This Mainstream? 1:37:30 – Living Ever Forward ----- Episode resources: Save 20% with checkout code EVERFORWARD at https://www.AX3.Life.com Watch and subscribe on YouTube Learn more at https://ax3.life/pages/science 

MOPs & MOEs is powered by TrainHeroic, the best coaching app on the planet. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here to get 14 days FREE and a consult with the coaches at TrainHeroic to help you get your coaching business rolling on TrainHeroic. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MOPs & MOEs delivers our training through ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TrainHeroic and you can ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠get your first 7 days of training with us FREE by clicking here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠To continue the conversation, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠join our Discord!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ We have experts standing by to answer your questions.An Instagram post a few weeks ago about how nicotine reduces bone density and slows healing no matter how it's consumed (smoking, vaping, pouches, etc.) sparked some surprisingly strong reactions. Since neither of us are experts on either nicotine's health effects or bone health in general, we knew we needed to find an expert to fill us in.Dr. Jocelyn Wittstein is a Sports Medicine Orthopaedic Surgeon and Associate Professor of Orthopaedic Surgery at Duke University specializing in the care of adolescent and adult athletes. She cares for soccer, lacrosse, and basketball teams as a team physician and consults with may regional gymnastics facilities for care of high level gymnasts. In Dr. Wittstein's clinical practice, approximately half of her focus is on adolescent and adult knee injuries, with patellofemoral stabilization being a common procedure. In addition to her clinical and research work on the patellofemoral joint, Dr. Wittstein also is a co-investigator on NIH funded studies of biomechanical and biochemical factors contributing to post-traumatic arthritis after ACL reconstruction and meniscus surgery. She is passionate about optimizing patient outcomes and safe return to sport after knee injuries.We talked to her a bit after recording about why different bios of her discuss such different work, and it's because she wears so many hats. Some things that bio missed were her particular emphasis on shoulder instability, work on the unique challenges faced by female athletes across the lifespan, and work on mitigating age related issues... It might not be clear from the broad span of research, but first and foremost she is a Full time surgeon. She was a collegiate gymnast at Cornell University, and she is a mother of five.Dr. Wittstein mentioned the app OSTEO-GAINS which helps with progressive plyometric loading will the goal of increasing bone density.

In episode 70 of Going anti-Viral, Peter Staley joins host Dr Michael Saag after giving the Martin Delaney presentation at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) entitled ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding. Mr Staley shares his inspiring story as a pioneering HIV and LGBTQ+ rights activist, recounting his journey from the early days of the AIDS crisis to groundbreaking activism leading to a seat at the table with clinicians and researchers in bringing life-saving treatments to people with HIV and AIDS. Dr Saag and Mr Staley also reflect on the recent era of anti-science activism during the COVID-19 pandemic and share their advice for young researchers who may be the generation of scientists that bring about a cure for HIV.0:00 – Introduction 2:30 – The early days of AIDS awareness6:23 – Peter's reflections on his positive HIV test result10:46 – Transitioning from Wall Street to activism12:11 – The formation ACT UP and impact of Larry Kramer15:22 – Channeling anger into activism17:47 – Targeting the FDA and the fight for drug access20:26 – The role of the NIH and Tony Fauci 24:10 – The Parallel Track: access to experimental drugs25:40 – The role of the Treatment Action Group (TAG) and the AIDS Clinical Trials Group (ACTG)26:32 – The breakthrough: viral load and undetectable levels31:18 – Reflections on COVID-19: activism in a new era33:45 – Prep4All: advocating for access to PrEP38:38 – Advice for young clinicians and closing remarksResources:Watch Peter Staley's presentation at CROI 2026 ''Annus Horribilis" and The War on Science: Thoughts on Resisting and Rebuilding YouTube:  https://youtu.be/p5kqUujWPCs PrEP4All: https://prep4all.org/ CROI 2026: https://www.croiconference.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Dr Anna Maria Bombardieri is a Stanford physician-scientist working with the NIH. She is helping design the RECOVER-TLC study on stellate ganglion block for long COVID. In this mini-episode, she explains the process, who's involved in this developing study, and what the goals are.Until March 3, 2026, the study design is available to review and open to public comments. Listen to Dr Bombardieri explain the study and watch/listen to our longer video explaining everything about stellate blocks. Watch on YouTube: https://youtu.be/CcGChFTZwvY Then, be part of the science! Share your input with RECOVER-TLC: https://recovercovid.org/news/recover-tlc-seeks-input-planned-study-possible-long-covid-treatmentJoin the LCMD community for support, science, and news. Sign up at http://LongCovidMD.com#longCOVID #COVID #fatigue #MECFS #POTS #medicine #scienceSupport the showSubscribe for free written summaries of each episode, resources, and more. LongCovidMD.substack.com/subscribe Support by donating at BuyMeACoffee

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the revolving door leadership at NIH's Institutes and Centers, UnitedHealthcare's controversial new Medicare Advantage policy, and a bill that would erase two decades worth of certain types of state nursing board discipline. Episode produced and hosted by Rachael Robertson. Sound engineering by

Introducing Brain Bytes, a new micro-cast hosted by Kelly Tremblay, PhD, neuroscientist, World Health Organization advisor, NIH grant reviewer, advocate, and professor. Brain Bytes features "byte"-sized nuggets of knowledge aimed at making neuroscience accessible for the senior living world.  In each episode, which will air on the fourth Friday of each month, Dr. Tremblay will share research-backed information related to aging and brain health. This week, she explores the different types of dementia and examines what evidence-based researchtells us about it. While encouraging listeners to take practical steps to support healthy aging, Dr. Tremblay explains that a significant portion of dementia risk may be modifiable. Factors such as education, physical activity, cardiovascular health, hearing and vision care, and social connection all play a role in supporting brain health across the lifespan. The following links accompany today's episode: • https://www.nia.nih.gov/health/alzheimers-and-dementia • https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/abstract • https://www.thelancet.com/infographics-do/dementia-risk We are grateful to Parker Health for their sponsorship of this micro-cast.

Sexual medicine is underfunded, misunderstood, and often dismissed. But it's also one of the most collaborative fields in healthcare. Dr. Tami Rowen recaps this year's ISSWSH conference and what it revealed about where the field is heading.Dr. Rowen is the current president elect of ISSWSH and has been instrumental in shaping sexual medicine education and research. We recorded this right after the 2026 ISSWSH conference in Long Beach, which had almost 600 attendeesone of our biggest conferences yet.We discuss the standout research from the meeting, including award winning work on sexual function after gender-affirming hysterectomy and why most top abstracts focused on sexual pleasure rather than prevention. We talk about the reality of research funding in sexual medicine, why industry support creates conflicts of interest that look bigger than they are, and how lack of NIH funding means we have almost no treatment options for conditions like vulvodynia.We also dive into testosterone therapy why it's controversial, what the data actually shows versus what social media claims, and why Dr. Rowen doesn't treat hormone levels but rather treats individuals with specific goals. We discuss body image after breast cancer surgery, lymphedema's impact on sexual function, and why technoference is contributing to the lowest rates of sex we've ever seen.HighlightsISSWSH focuses on sexual pleasure and quality of life, not just prevention of pregnancy and STIs.Research funding for vulvodynia is $4 million annually versus $800 million for breast cancerthat's one grant versus hundreds.Testosterone therapy should treat symptoms and goals, not hormone levels or deficiencies.Body image and sexual function outcomes are significantly worse after mastectomy versus lumpectomy, even though cancer outcomes are equal.Technoference (technology interference) is contributing to historically low rates of sexual activity.If you're a clinician interested in sexual medicine, consider attending the ISSWSH Fall Course for foundational education and the annual meeting for cutting-edge research. If you're a patient navigating any issues and not currently getting help, know that there are practitioners out there who want to help you.Subscribe to the podcast and share this episode with anyone who wants to learn more about sexual medicine, menopause, or women's health education.Get in Touch with Dr. RowenWebsiteInstagramGet in Touch with Me: WebsiteInstagramYoutubeSubstackMentioned in this episode:GSM CollectiveThe GSM Collective - Chicago Boutique concierge gynecology practice Led by Dr. Sameena Rahman, specialist in sexual medicine & menopause Unrushed appointments in a beautiful, private setting Personalized care for women's health, hormones, and pelvic floor issues Multiple membership options available Ready for personalized women's healthcare? Visit our Chicago office today. GSM Collective

Dr. Jay Bhattacharya, Head of NIH and Acting CDC Director, tells about reform of a broken system, and how he's launching a vaccine injury effort. Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.

Dr. Roger McFillin argues that Western allopathic medicine and psychiatry have medicalized normal human suffering by reducing emotions to biological or chemical reactions, turning symptom checklists into fixed identities, and sustaining a drug-driven "sick care" system that creates lifelong customers. He contrasts this with viewing emotions as powerful energy meant to be moved into creation and transformation, cites psychoneuroimmunology, and warns that suppressing fear and distress with pharmaceuticals can worsen long-term outcomes. The conversation covers exposure-based approaches to unlearn fear, the role of media, social media, and advertising in provoking fear and keeping people in an unconscious "drift" state, and the importance of intentional stillness, solitude (distinct from loneliness), prayer or silent meditation, and reducing phone use—especially at the start of the day—to become more conscious and intentional.    McFillin discusses how diagnostic labels like depression and anxiety shape identity, limit choices, and contribute to chronicity and polypharmacy. He contrasts PTSD with post-traumatic growth, emphasizing processing trauma memories, facing avoided situations, challenging overgeneralized threat beliefs, and practicing forgiveness and self-compassion while also taking ownership where appropriate. They also discuss the perceived harms of the "toxic masculinity" concept, men's wellbeing, the loss of wise elders, and how men often bond and cope through shared activities. Dr. Roger McFillin is a clinical psychologist and trauma recovery expert who challenges the medicalization of normal human emotions. With a focus on emotional resilience and personal growth, he specializes in exposure therapy and psychoneuroimmunology, exploring the connection between mind, emotions, and immune health. Dr. McFillin advocates for self-regulation and transforming emotional energy into healing, critiquing the overuse of pharmaceuticals in modern mental health treatment. Through his Substack, Radically Genuine, and podcast, Dr. McFillin educates individuals on overcoming fear, achieving stillness, and reconnecting with their true selves. His work empowers people to shift from a victim mindset to one of active growth, using trauma as a catalyst for resilience and positive change.   Science & Medicine   Psychoneuroimmunology   Overview & science (NIH): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130991/   Exposure Therapy   Wikipedia overview: https://en.wikipedia.org/wiki/Exposure_therapy   Cleveland Clinic explanation: https://my.clevelandclinic.org/health/treatments/25067-exposure-therapy   Anxiety & OCD exposure-based approaches (IOCDF): https://iocdf.org/about-ocd/treatment/erp/   Heart Coherence   HeartMath Institute overview: https://www.heartmath.org/heart-coherence/   Psychiatric Diagnosis & DSM   Critique of DSM and diagnostic categories: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195174/   Psychiatric diagnosis controversies: https://www.apa.org/monitor/2013/04/diagnosis   Psychology & Healing   Post-Traumatic Growth vs. PTSD   Scientific overview of post-traumatic growth: https://www.apa.org/monitor/2014/01/psychological-recovery   Journal article on PTG vs PTSD: https://www.sciencedirect.com/science/article/abs/pii/S0272735814000412   Forgiveness and Healing   Psychology Today on forgiveness: https://www.psychologytoday.com/us/basics/forgiveness   Research evidence on forgiveness and wellbeing: https://journals.sagepub.com/doi/10.1177/1745691614568356   Self‑Healing Practices   Grounding / Earthing   What is grounding/earthing? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378297/   PEMF (Pulsed Electromagnetic Field) Therapy   Basics of PEMF therapy: https://www.health.harvard.edu/pain/pulsed-electromagnetic-field-therapy   Meditation & Stillness   Mindfulness & stillness research: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422583/   Psychology Today on solitude and healing: https://www.psychologytoday.com/us/blog/hide-and-seek/201209/finding-solitude-its-benefits-and-challenges   Cultural & Media Influence   Mind Control & Fear Provocation   The psychology of fear in media messaging: https://www.frontiersin.org/articles/10.3389/fpsyg.2020.566245/full   Media influence and persuasion research: https://www.communicationtheory.org/agenda-setting-theory/   Toxic Masculinity   Research overview on toxic masculinity: https://www.apa.org/advocacy/health-men/guidelines   What toxic masculinity means: https://www.psychologytoday.com/us/blog/the-masculine-mind/201802/what-toxic-masculinity   Dr. Roger McFillin Content   Substack (Radically Genuine): https://drmcmillan.substack.com   Show Notes 00:00 Emotions as Energy 00:33 Medicalizing Suffering 02:44 Exposure Beats Suppression 05:18 Fear and Mind Control 10:21 Stillness vs Loneliness 14:47 Simple Stillness Practices 20:12 Morning Intention Rituals 25:56 Labels and Identity Traps 31:26 Systemic Treatment Harm 32:53 Depression Label Identity 35:08 Sadness Versus Pathology 36:10 PTSD And Growth 38:24 Processing Trauma Fully 41:44 Practical Recovery Steps 45:48 Forgiveness And Ownership 50:37 Toxic Masculinity Debate 56:12 Men Friendship And Elders 01:01:05 Closing Plugs Farewell 38:24 How PTSD Develops 41:44 Practical Trauma Recovery 45:48 Forgiveness and Ownership 50:37 Toxic Masculinity Debate 56:12 Male Friendship and Elders 01:01:05 Closing and Where to Follow   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

This week on the podcast, AgingIN CEO, Susan Ryan, welcomes Kelly Tremblay, PhD, a neuroscientist, World Health Organization advisor, NIH grant reviewer, advocate, and professor. As a first-generation college student, Kelly's path was shaped by lived experience. Growing up with a father who had multiple sclerosis, she became an early advocate for accessibility and healthcare equity. At the University of Washington, Kelly led research focused on the aging brain and collaborated with the National Institutes of Health and the World Health Organization to help translate science into global health strategies. In this wide-ranging conversation, Susan and Kelly discuss health literacy and Kelly's desire to bridge the gap between research and real life by making science accessible, practical, and actionable. This goal comes to life in the launch of Brain Bytes, a new monthly micro-cast debuting Friday, Feb. 27, with new episodes dropping on the fourth Friday of each month. Designed to deliver bite-sized, evidence-based insights, Brain Bytes will focus on six key areas of brain health: nutrition, hearing loss, vision loss, mood, cognition, and balance Throughout the episode, Kelly reminds us that knowledge is power—but only if it's accessible. Brain Bytes aims to empower listeners with clear, plain-language information that supports better decisions, stronger advocacy, and healthier aging.

Announcements: SOTU @5:47 Follow-ups: FDA does a 180, decides it will review Moderna's mRNA vaccine @8:51 Fetterman at SOTU @9:40 Religious Nonsense: Tennessee bill would require public schools to teach the Bible @9:45 Earlier this week, another big Texas school district said “no, thanks” @11:24 Hegseth invited pastor to lead Pentagon prayer service @12:10 State of the Union update @14:23 PRRI released a new report on Christian Nationalism @15:55 News: Armed Man Is Fatally Shot at Mar-a-Lago @18:15 Trump Considers Targeted Strike Against Iran @22:22 Jared's take on the Men's Hockey team @26:19 Ambassador Mike Huckabee suggests Israel has God-given right to Middle East @26:47 Andy Win arrested @29:41 Peter Mandelson, Ex-Ambassador to the U.S. Arrest @33:41 Politics: DoW Christian Service Draws Complaints @35:37 Ohio mayor arrested on voyeurism charges @42:34 Health/Medicine/Science: NIH Director Jay Bhattacharya the new interim director of the CDC @48:56 Uproar in MAHA because glyphosate @49:37 Skeptical Inquirer Experts warn about NIH director @57:14 U.S. Creating a brand-new parallel WHO org @57:43 Final Stories: Flavor Flav invites USA women's hockey team to 'real celebration' @58:25

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3305: Danielle Omar breaks down the essentials of omega 3 fatty acids, explaining their structure, the different types (ALA, EPA, and DHA), and why they're crucial for brain, heart, and joint health. You'll also learn which foods to prioritize and how to get enough omega 3s through simple daily choices that support overall well-being. Read along with the original article(s) here: https://foodconfidence.com/2018/11/16/everything-youve-ever-wanted-to-know-about-omega-3-fatty-acids/ Quotes to ponder: "Long story short, omega 3 fatty acids are essential polyunsaturated fats." "EPA supports your body in a ton of different ways. Getting enough EPA is super important for brain health and decreasing inflammation." "Omega 3s support heart health in some major ways! They can reduce triglycerides and blood pressure, increase HDL ('good') cholesterol, and help prevent plaque build up in your arteries." Episode references: USDA FoodData Central (Omega-3 Content of Foods): https://fdc.nal.usda.gov Recommended Daily Intake for Omega 3s (NIH): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer Learn more about your ad choices. Visit megaphone.fm/adchoices

As institutions like the NIH and CDC face challenges, many professionals find themselves at a crossroads, forced to pivot their research focus to secure funding while grappling with a loss of passion and purpose. But what if there's a better way? Join Kemi as she explores pivoting versus strategic framing. Learn the difference and how to choose.  Coming soon: Applications for the Get That Grant® April 2026 cohort will open to the waitlist. Join here: www.kemidoll.com/gtgwaitlist If you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations. Text Dr. Kemi directly.

In the second installment of this three-part series, Dr. Stacey Clardy and Max Goldman discuss neuroscience research and the BRAIN Initiative.  Stay updated with everything related to Neurology on the Hill. Show transcript:  Dr. Stacey Clardy:  Hi, this is Stacey Clardy. We are going to continue with our three-part series today about the top advocacy issues covered at Neurology on the Hill 2026 in Washington, DC. Again, as many of you know, this is the AAN's annual advocacy fly-in event. Neurologists come from all over the US to Washington and meet with elected representatives to discuss issues of high importance to allow us to continue providing high-quality care to patients in the US with neurological diseases. In the first minute, we discuss the topic of Medicare, and I have with me again, Max Goldman, director of Congressional Affairs from the AAN legislative team, to talk to us about issue number two, which is neuroscience research, and specifically the BRAIN Initiative. Max, what are we going to discuss about neuroscience research? What do we need to happen in order to continue doing high-quality research? Max Goldman: So, this one is so important, and there's this wonderful program at the NIH called The BRAIN Initiative. This was founded in 2013, really reinforced in 2016 with the 21st Century Cures Act. It's just funding for basic research into how the brain works, right? And the idea behind this is that if we can understand how the brain works, we can find the next generation of treatment or cures for neurological conditions, psychiatric conditions, and issues that go through the brain. This year, we are in a precarious position. Mandatory funding for this program is expiring, and so we're going to lose a lot of money and a lot of opportunities to provide more grants to people to figure out how the brain works. So, what we are doing on Neurology on the Hill is we're asking members of Congress to support $468 million in funding in fiscal year 2027 for the BRAIN Initiative, so we can keep up the good work and keep working towards the next generation of treatments and cures for neurological conditions. Dr. Stacey Clardy: So important. Thank you, Max. To learn more about this issue and the other two issues, you can go to AAN.com. Click on advocacy. And stick with us for the third Neurology Minute, where we will get to the final issue to be discussed, telehealth. 

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3305: Danielle Omar breaks down the essentials of omega 3 fatty acids, explaining their structure, the different types (ALA, EPA, and DHA), and why they're crucial for brain, heart, and joint health. You'll also learn which foods to prioritize and how to get enough omega 3s through simple daily choices that support overall well-being. Read along with the original article(s) here: https://foodconfidence.com/2018/11/16/everything-youve-ever-wanted-to-know-about-omega-3-fatty-acids/ Quotes to ponder: "Long story short, omega 3 fatty acids are essential polyunsaturated fats." "EPA supports your body in a ton of different ways. Getting enough EPA is super important for brain health and decreasing inflammation." "Omega 3s support heart health in some major ways! They can reduce triglycerides and blood pressure, increase HDL ('good') cholesterol, and help prevent plaque build up in your arteries." Episode references: USDA FoodData Central (Omega-3 Content of Foods): https://fdc.nal.usda.gov Recommended Daily Intake for Omega 3s (NIH): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer Learn more about your ad choices. Visit megaphone.fm/adchoices

Discover how to lose weight without Ozempic using 5 evidence-backed strategies. This episode breaks down why insulin resistance is the real driver of weight gain and how cutting processed foods, eating only when hungry, fasting, weight resistance training, and detoxification can help you lose weight naturally and sustain it long-term — no prescription required. FEATURED PRODUCT The Good Poops Protocol is designed to support the exact systems discussed in this episode — liver detoxification, gut health, and blood sugar regulation. 

The National Institutes of Health continued to lean into the use of artificial intelligence last year. The NIH has now initiated more than 100 AI pilots over the last few years. Those efforts ramped up as the health agency also navigated staffing cuts and other turmoil in 20-25. For more, Federal News Network's Justin Doubleday joins me now.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this Salcedo Storm Podcast:Dr. Robert Malone, is a bioethicist who is an internationally recognized scientist in virology and immunology. He was appointed to the Advisory Committee on Immunization Practices by HHS Secretary Kennedy.

Host: Mindy McCulley, MS, Extension Specialist for Instructional Support, Family and Consumer Sciences Extension, University of Kentucky  Guests: Nathan Vanderford, PhD Director, Appalachian Career Training in Oncology Program, Markey Cancer Center, Kameron Jackson and Matthew Sanders, ACTION Program student participants Cancer Conversations Episode 72 Welcome to Cancer Conversations on Talking FACS with host Mindy McCulley. In this episode we hear from Dr. Nathan Vanderford, director of the NIH-funded ACTION (Appalachian Career Training in Oncology) program, and students Kameron Jackson and Matthew Sanders about how the program engages Eastern Kentucky high school and undergraduate students in cancer education, lab research, clinical shadowing, mentorship, and community outreach. Topics covered include student experiences in research labs and mentorship, the program's recruitment across the 54 Appalachian counties, and a unique writing project that produced four books of personal and realistic fictional stories about cancer in Eastern Kentucky. Kameron and Matthew describe how writing helped them process family history, spark conversations about cancer, and build communication skills alongside scientific training. Key takeaways: ACTION provides hands‑on research and outreach opportunities that change career trajectories, creative writing can open difficult conversations about cancer in communities, and the program aims to broaden access across the region. Find the students' stories and the full book linked in the episode show notes and visit Markey.uky.edu or the UK Markey Cancer Center Facebook page for more information. Click the images below to hear student read excerpts from Cancer in Appalachia: A Collection of Youth Told Stories   For more information about : Appalachian Career Training in Oncology Program ACTION Books Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey

Vital Mindset & Discipline PodcastFIVE PRIMARY POINTS of the PODCASTSpirituality Is Foundational to Mental Health and ResilienceThe episode argues that spirituality—defined as a belief in something bigger than oneself—is not merely philosophical but scientifically supported as a fundamental resource for promoting mental health. Peer-reviewed data cited in the podcast link spirituality and religion to improved emotional resilience, inner serenity, compassion, and psychological well-being.Religion and Spirituality Have Measurable Neurobiological and Social EffectsEngaging in spiritual or religious practices activates brain regions involved in emotional regulation and social perception. Research discussed suggests these practices strengthen social bonds, enhance compassion, reduce stress, and may improve immunity, cardiovascular outcomes, and overall longevity.Spiritual Well-Being Can Be Measured and StrengthenedA nine-question NIH survey (Experience of All Life Stressors Short Form) is presented as a concise tool to assess spiritual well-being, including purpose, peace, gratitude, compassion, presence, and connection to a higher power. The key message: we cannot eliminate suffering, but we can train ourselves to respond to it better by strengthening these dimensions.Forgiveness and Purpose Are Powerful Biological ToolsForgiveness is framed not just as a moral virtue but as a physiological stress-reduction strategy. Research on the REACH method shows forgiveness reduces anxiety and depression. Similarly, a strong sense of purpose is associated with increased longevity. Both are actionable ways to deepen spiritual vitality.Awareness of Mortality Clarifies Meaning and ActionThrough the “shovel next to the grave” reflection, the episode emphasizes that recognizing life's fragility sharpens focus on purpose, service, and compassion. Rather than being morbid, contemplating mortality helps individuals live more intentionally—working hard at work worth doing, as quoted from Teddy Roosevelt.Copyright VyVerse, LLC. All Rights Reserved. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit vitalityexplorers.substack.com/subscribe

Dr. Raymond Barnhill on Diagnostic Drift, Uncertainty, and the MPATH-Dx V2.0 Approach to Melanocytic LesionsIn this episode of The Girl Doc Survival Guide, Christine interviews Dr. Raymond Barnhill, a world-recognized dermatopathology expert known for work on diagnostically challenging melanocytic lesions, melanoma pathology references, and contributions to WHO skin tumor classification and AJCC melanoma staging. Dr. Barnhill shares career anecdotes and key communities at Yale and in Boston, collaborations with numerous melanoma leaders, and the founding of the North American Melanoma Pathology Study Group and the International Melanoma Pathology Study Group, as well as participation in the NIH-funded MPATH Study Group. The discussion focuses on overdiagnosis, underdiagnosis, and diagnostic discordance in melanocytic lesions, including evidence of diagnostic drift toward calling more lesions melanoma over time and the overlap between melanoma criteria and atypical/dysplastic nevi. He describes MPATH research, explains the revised MPATH-Dx V2.0 schema, explicitly recognizing uncertainty along a continuum rather than a strict benign/malignant threshold. He emphasizes practical diagnostic approaches including measuring lesion size (noting a 4 mm threshold associated with conventional dysplastic nevi and increasing concern at larger sizes), focusing on key architectural features (junctional nest variation/disarray and lentiginous proliferation), using nuclear size relative to keratinocyte nuclei (including a 1.5× threshold and counting atypical cells per high-power field) while accounting for site-specific pitfalls such as scalp nevi. The conversation also covers “gestalt” versus systematic review, the importance of due diligence using full clinical and morphologic information before ancillary testing, and cautions against overreliance on immunohistochemistry or molecular tests. Dr. Barnhill closes with career advice ends with a message that setbacks can be opportunities for growth.00:00 Welcome + Meet Dr. Raymond Barnhill (Dermatopathology Legend)01:51 Career Origins & Melanoma Pathology Mentors (Yale → Boston)03:59 Building Melanoma Pathology Study Groups (North American & International)05:57 Overdiagnosis, Diagnostic Drift & Why Discordance Happens09:43 Inside the MPATH Study: Measuring Interobserver & Intraobserver Agreement11:39 MPATH-Dx V2.0 Explained: Standardized Classes & Treatment Guidance13:59 Redefining “Low-Risk” Melanoma: Stringent pT1a Criteria + Embracing Uncertainty18:47 Practical Grading Tips: Lesion Size, Architecture & Nuclear Atypia Thresholds22:42 Gestalt vs Due Diligence: Avoiding Traps + Using IHC/Molecular Wisely (PRAME)28:39 Career Advice: Passion, Mentors, Community + Final Reflections

On the DSR Daily for Monday, we discuss the DOJ's ludicrous claims regarding the Epstein Files Transparency Act, DHS attempting to have tech companies unmask anti-ICE accounts, the vacuum of leadership at the NIH, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Monday, we discuss the DOJ's ludicrous claims regarding the Epstein Files Transparency Act, DHS attempting to have tech companies unmask anti-ICE accounts, the vacuum of leadership at the NIH, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Monday, we discuss the DOJ's ludicrous claims regarding the Epstein Files Transparency Act, DHS attempting to have tech companies unmask anti-ICE accounts, the vacuum of leadership at the NIH, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Eye Believe Podcast, we're joined by Dr. Zack Oakey, a board-certified ophthalmologist and ocular oncologist with extensive training in retinal disease and ocular oncology.   Dr. Oakey shares his unique approach to using social media—especially TikTok—to educate patients, combat misinformation, and make complex ocular melanoma topics more accessible. Drawing from his training at institutions including the NIH, UC Irvine, the University of Wisconsin, and the Cleveland Clinic's Cole Eye Institute, he offers valuable insight into how trusted medical information can reach patients where they already are.   This episode blends medical expertise with modern communication, offering both reassurance and actionable information for patients, caregivers, and advocates alike.   Tune in to hear how education, accessibility, and innovation can make a real difference in the OM community.

This episode covers: • Mic-628 Could Reset Your Body Clock and Cut Jet Lag in Half A new circadian drug candidate, Mic-628, has demonstrated the ability to shift the body's internal clock and significantly reduce jet-lag recovery time in early human studies. In controlled simulations, participants experienced faster realignment of their sleep-wake cycles and improved daytime performance compared to standard approaches like melatonin and light timing alone. Dave explains how this compound targets a core clock pathway, why eastbound travel is biologically harder than westbound, and how pharmacologic chronotherapy could become a serious performance tool for frequent travelers and shift workers. He also connects circadian alignment to obesity, insulin resistance, cardiovascular risk, and cognitive decline, outlining what this breakthrough could mean if safety data continues to hold. • Source: https://www.sciencedaily.com/news/top/ • Late-Life Depression May Signal Parkinson's or Dementia New research from Shanghai Jiao Tong University found that new-onset depression in older adults is strongly associated with increased risk of Parkinson's disease and dementia. Dave reframes this finding as a brain health signal rather than a purely psychiatric issue, explaining how inflammation, microglial activation, vascular health, and neurodegeneration intersect with mood changes. He breaks down why sudden depression in someone with no prior history may warrant deeper cognitive testing, sleep evaluation, and metabolic screening instead of simply prescribing an antidepressant and moving on. This story highlights the importance of treating mood shifts as early biological data in a longevity framework. • Source: https://www.sciencedaily.com/releases/2026/02/260210040623.htm • Speed-Training Brain Games Reduced Dementia Risk by 25 Percent The long-running NIH-funded ACTIVE trial found that a specific speed-of-processing training program reduced dementia incidence by roughly 25 percent over two decades. Unlike memory or reasoning exercises, this visual processing speed protocol produced measurable long-term protection. Dave explains why reaction time and processing speed may be core capacities tied to cognitive resilience, and how structured brain-training programs descended from this research can be treated like strength training for the mind. Instead of vague advice to “stay mentally active,” this data supports building deliberate, trackable cognitive training into a midlife longevity plan. • Sources: – NPR summary: https://www.npr.org/2026/02/09/nx-s1-5702423/modest-mental-exercise-can-reduce-risk-of-dementia-for-decades-study-finds – Psychology Today analysis: https://www.psychologytoday.com/us/blog/build-your-brain/202602/new-study-means-the-age-of-dementia-prevention-begins-now • Moderate Coffee Intake Linked to Slower Brain Aging A large analysis of roughly 130,000 participants found that moderate coffee consumption, about one to three cups daily, was associated with markers of slower brain aging and lower dementia risk. Dave explains why moderate, morning-weighted caffeine intake may align acute performance benefits with potential long-term brain protection. He breaks down the dose curve, why more is not necessarily better, and how to use coffee strategically without compromising sleep or circadian rhythm. Rather than framing caffeine as either a miracle or a villain, this study supports intelligent, personalized dosing as part of a broader brain-health stack. • Source: https://www.nature.com/articles/d41586-026-00409-y • Kratom Crackdowns and the Future of Supplement Freedom Regulators are tightening restrictions on high-potency kratom derivatives such as 7-hydroxymitragynine, with new bans and stricter warning requirements emerging at the state level. The FDA continues to treat kratom and its concentrated derivatives as unapproved drugs with opioid-like effects, while local jurisdictions are targeting specific formulations linked to adverse events. Dave breaks down how this represents a broader shift in how edge-case compounds are regulated, why supply volatility and underground markets can increase risk, and what this means for biohackers who experiment with gray-area tools. He also explains how evolving enforcement strategies could shape future access to peptides, nootropics, and other advanced compounds. • Sources: – Kansas City coverage: https://www.kshb.com/news/local-news/strong-high-weak-laws-7-oh-ban-kratom-regulation-moves-forward-in-kansas-city-missouri – Florida policy coverage: https://www.wgcu.org/health/2026-02-04/kratom-advocates-tout-its-properties-but-legislators-want-strict-warnings-about-the-herbal-supplement – Legal landscape analysis: https://www.lumalexlaw.com/2025/10/09/kratoms-legal-future-how-states-and-the-federal-government-are-responding/ – FDA background: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom All source links are provided for direct access to the original reporting and research. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on circadian biology, neurodegeneration signals, cognitive training, caffeine strategy, and supplement regulation. Host Dave Asprey connects emerging science, behavioral data, and policy shifts into practical frameworks you can use to build a resilient, adaptable health stack. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Mic-628 circadian drug, jet lag recovery science, chronotherapy biohacking, late life depression dementia risk, Parkinson's prodromal symptoms, ACTIVE trial dementia prevention, speed of processing training, brain aging coffee study, moderate caffeine longevity, kratom regulation 7-OH, supplement law biohacking, neurodegeneration early signals, cognitive performance training, circadian rhythm optimization, metabolic brain health, biohacking news Thank you to our sponsors! - Antarctica Trip | Join me in Antarctica from March 8–17, 2026. Visit https://www.insiderexpeditions.com/future and use code DAVE for $1,000 off.- TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.Resources: • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 - Introduction 0:18 - Story #1: Circadian Drug for Jet Lag 2:00 - Story #2: Depression as Early Warning Sign 3:30 - Story #3: Brain Processing Speed Training 4:56 - Story #4: Coffee and Brain Health 6:24 - Story #5: Kratom Regulation 8:21 - Weekly Roundup 9:25 - Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Research years. Professional development time. Career exploration.Whatever you call it, stepping out of clinical residency can feel confusing, intimidating, and oddly hard to plan for. In this episode of Behind the Knife, our BTK Surgical Education Fellows Drs. Elizabeth Maginot, Nicole Petcka, Agnes Premkumar, Kara Button, Emma Burke, and Michelle LaBella sit down with Dr. Daniel Nussbaum, Associate Professor of Surgery at Duke University and leader in the Duke Residency Research Fellowship Program, to unpack dedicated resident profressional development time really looks like, who it helps, who it doesn't, and how to make the most of it if you choose to step out of clinical training.Together, the group tackles:·       Why “research years” are often better thought of as professional development time·       Whether taking time out of residency is actually necessary for fellowship or an academic career·       How to find the right mentor—and why there's rarely a “perfect” project·       Practical advice on setting boundaries, saying yes (and no), and managing unstructured time·       A clear, resident-level overview of funding options, including:- NIH T32 and F32 grants- NIH Loan Repayment Program (LRP)- Society, foundation, and departmental funding·       What faculty and program leadership look for when supporting resident research·       Lessons the panel wishes they'd known before starting research timeWhether you're a medical student curious about residency structure, a resident debating whether to step out, or faculty mentoring trainees through career development, this episode offers candid insight, real examples, and reassurance that there's more than one “right” path. High-Yield Takeaway: You don't need research time to be a great surgeon—but if you want to grow skills outside the OR, this may be the rare window to do it thoughtfully (and even enjoy it).Resources & Links Mentioned:NIH Funding & Training Programs·       NIH RePORTER – Explore active NIH-funded grants and training programs https://reporter.nih.gov/#/·       NIH T32 Institutional Training Grants https://grants.nih.gov/funding/activity-codes/T32·       NIH F32 Individual Postdoctoral Fellowshiphttps://grants.nih.gov/funding/activity-codes/F32·       NIH Loan Repayment Program (LRP) https://grants.nih.gov/funding/funding-categories/lrp·        Foundational & Society Grants(Not a comprehensive list; examples discussed in the episode)·       Association of Program Directors in Surgery (APDS) Job Board https://apds.careerwebsite.com/jobs/? ·       American College of Surgeons (ACS) – Resident research funding https://www.facs.org/for-medical-professionals/professional-growth-and-wellness/scholarships-fellowships-and-awards/resident/resident-research/·       Association for Academic Surgery (AAS) – Resident research funding primer https://www.aasurg.org/resident-research-funding-primer/·       American Surgical Association (ASA) – Research awards & fellowships https://americansurgical.org/awards_Fellowship.cgi·       Society of University Surgeons (SUS) – Resident Research Scholar Awards https://www.susweb.org/resident-scholar-research-awards/? ·       American Association for the Surgery of Trauma (AAST) – Scholarships & grants https://www.aast.org/professional-development/scholarships.html·       Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) – Research grants https://www.sages.org/research/research-grants/ Helpful Application Resources·       NIH Biosketch Format & Instructions https://grants.nih.gov/grants-process/write-application/forms-directory/biosketch Sponsor Link: Medical Education master's program at the University of Pennsylvania Graduate School of Education - https://www.gse.upenn.edu/btkPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Can I Moderate? Why This Question Matters More Than We Talk About For most of my recovery journey, I held a pretty firm belief: If you're questioning your drinking, the answer is probably abstinence. That belief came from both lived experience, as well as observing other people who struggle with alcohol. Personally, I never drank normally. From the very first drink, the switch flipped on—and it stayed on. I hit a hard bottom early, and after years of trying to moderate, the answer for me was clear: I could not moderate. As it turned out, for me abstinence meant freedom. And still… Over time, something softened in me. Not because I changed my relationship with alcohol—but because I started listening more closely to other people's experiences. The Question Everyone Has to Answer for Themselves I've come to believe this: "Can I moderate?" is not a denial question. It's a developmental one. For many people, it's the pivot point of their entire recovery journey. Some people answer it quickly. Some answer it painfully. Some don't answer it until years—sometimes decades—later. But skipping the question doesn't make it disappear. And that's why my conversation with Nick Allen, CEO and co-founder of Sunnyside, felt so important. Nick grew up in an AA household. Both of his parents are in long-term recovery. He understands abstinence deeply—and still, his own relationship with alcohol took a different path. Instead of waiting for a crisis, he began asking a quieter question early on: What does a healthy relationship with alcohol look like for me—right now? That question eventually became Sunnyside: a platform designed to help people explore change before things fall apart. The Missing Middle Here's the reality I see again and again: Most people are offered two options: Figure it out Quit forever And when those are the only choices on the table, a huge number of people choose to keep trying to figure it out. Not because they're reckless. Not because they don't care. But because abstinence can feel overwhelming, stigmatizing, or premature—especially for people who are still functioning "well enough." Research suggests there's often a 10-year gap between when alcohol becomes a problem and when someone seeks help. Ten years. Think about what happens in ten years: Careers strained Health eroded Relationships damaged Kids absorbing instability they can't name yet Waiting is not neutral. Why Willpower Isn't the Answer One thing Nick and I aligned on immediately: Willpower is a terrible long-term strategy. Willpower is finite. It's lowest at the exact moments people need it most: After a long day During stress At the witching hour (5–7pm) On Fridays when it's "been a week" Sunnyside takes a different approach: Decisions are made ahead of time, when clarity is high Habits are supported with structure, not shame Accountability is externalized, not moralized This is how real behavior change works. A Word About Naltrexone (And Nuance) We also talked openly about naltrexone, a medication that's been FDA-approved for decades to help reduce alcohol cravings. Here's what matters: It doesn't make people sick It doesn't require abstinence It reduces the reward loop that drives compulsive drinking I've had clients use it successfully—particularly high-functioning people who struggled with the "off switch," not daily drinking. But for people earlier in the process—people quietly wondering, "Is this still working for me?"—tools like this can interrupt years of silent suffering. Language Matters More Than We Think One of the most powerful parts of this conversation was about vocabulary. Words like addict, alcoholic, relapse, recovery—they carry weight. For some people, they offer clarity and belonging. For others, they create shame, fear, and avoidance. If the language feels too heavy, people wait. Sunnyside intentionally avoids labels and instead talks about: Alcohol overuse Habit change Awareness Experimentation That shift alone can make change feel possible. Where I Land Now I'm still sober and have no desire to drink again. I still believe abstinence is the right path for most people who struggle with alcohol. And I also believe we need earlier, gentler, more honest entry points into change. The goal of sobriety—or moderation, or reduction—isn't the absence of alcohol. It's: Freedom Health Presence A life that actually works If someone can get there sooner, with less damage along the way, I'm all for it.     Action Steps If this resonated, here are a few grounded next steps: Ask the question honestly Is alcohol adding to my life—or quietly taking from it? Move from judgment to curiosity You don't need a label to run an experiment. Plan ahead of cravings Decisions made in advance beat willpower every time. Seek support early Coaching, tracking, community, and medical tools are preventative—not last resorts. Protect what already works If abstinence is serving you, honor that. No need to second-guess stability.     Resources Sunnyside: https://www.sunnyside.co/arlina Sunnyside Med (Naltrexone access) NIH research on alcohol use disorder and treatment gaps AA and abstinence-based recovery programs (for those who already know)     If you're listening to this podcast, reading this post, or even asking the question quietly to yourself—you're already earlier than most. And earlier matters.   Guest Contact Info: https://get.sunnyside.co/arlina

It's been three full years since the Ohio state government decided to detonate derailed train cars containing vinyl chloride in the village of East Palestine.You might remember the apocalyptic imagery that came out of that explosion—it looked like a nuclear bomb had gone off.Three years later, anecdotal evidence is showing that the residents are experiencing thyroid disease, cancers, respiratory problems, neurological issues, asthma, and other problems.The National Institutes of Health (NIH) has now announced a $10 million research project to study the long-term health effects on the people living there.Let's review what took place there in 2023, what the effects appear to be now, as well as what the NIH is doing about it.

In this no-holds-barred interview, Dr. Jay Bhattacharya, director of the National Institutes of Health, breaks down how the world's largest public funder of biomedical research is changing under his leadership.Bhattacharya, a former professor of Stanford University, public health expert, and coauthor of the anti-lockdown Great Barrington Declaration, was sworn in as director of the NIH in April last year.With an annual budget of almost $50 billion, the NIH sets the direction of research at universities, medical centers, and research institutes across America.It encompasses 27 institutes and centers that cover different areas of health and employ some 20,000 people. One of those is the National Institute of Allergy and Infectious Diseases, which was headed by Dr. Anthony Fauci for nearly 40 years.The NIH, Bhattacharya told me, “really hasn't had a change in leadership in decades. ... We've had new directors, but the fundamental structure and direction of the NIH has been basically the same until last year.”Bhattacharya says his top priority is to end the practice of “funding the scientific enterprise for the sake of funding science” and ensure that NIH-funded scientific research actually produces better health outcomes for the American people. The goal should be improvements in health and longevity, not just more scientific papers, he says.During our interview, we covered a lot of ground, including:-Has the NIH completely stopped funding gain-of-function research?-Is the NIH continuing to fund research with China?-How has funding for international research institutes been restructured?-Has the NIH stopped funding all research grants related to diversity, equity, and inclusion initiatives?-What is being done to reverse the politicization of science?-What is the NIH doing to help those who suffered injuries from the mandated COVID-19 mRNA vaccines?-What can the NIH do to alleviate the massive replication crisis in research?-How does he view the controversy surrounding vaccines and autism? Is the NIH looking into potential links?-How is the NIH restructuring the allocation of funding?What America needs, Bhattacharya told me, is a “second scientific revolution,” saying: “The NIH has the capacity to induce that second scientific revolution. That's what I'm going to work toward for the next few years.”Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

CEREMONIAL SCI OP - 02.09.2026 - #914 BestPodcastintheMetaverse.com Canary Cry News Talk #914 - 02.09.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for a discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers Michael B*** Sir LX Protocol Baron of the Berrean Protocol***   Producers of TREASURE (CanaryCry.Support) Cage Rattler Coffee   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   SUPPLY DROP Calendar and Goldback bonus to new sign ups   OLYMPICS DEVIL 2:48 Ring "Search party"  Clip: Olympics Pentagram Clip: Spiral imagery at opening ceremony (X) Clip: Israeli's boo'd at opening ceremony, walking through Stargate (X) Clip: Israel boo'd? (X)  Israeli Bobsled team Robbed (Fox) → Clip: Milan protests are intense → Clip: more protest footage AP gives no reason for riots at Olympics (AP) → DHS post, sent ICE agents to Italy for Olympics, quotes Variety (X)  Suspected saboteurs hit Italian rail network near Bologna, police say (CBC)   EPSTEIN 1:33:28 Note: France former culture minister resigns over Epstein (AP) Cclip: Ro Khana on the destruction of the royal family (cnn)  'Evil': Conservatives ERUPT on Steve Bannon Over Epstein Revelations (MediaIte) Epic Games denies rumors about presence of Jeffrey Epstein alive and playing Fortnite (MSN) Epstein heavily involved in "Micro-transactions" in video games Epstein WoW account and money laundering (IBT)   -Epstein Reportedly Ordered Multiple 55-Gallon Sulfuric Acid in 2018: 'Likely Used to Dissolve Bodies of Children' (IBT) → 330-Gallon Sulfuric Acid Purchase in 2018 Sparks Speculation (Criminal Watch) → He ordered 6x55 gallons which = 330 (X)   SCIENCE IS TRUTH 2:26:33 1-CRISPR removes chromosome to cure Down syndrome (Time of India) → Innovative Approach Developed for Removing Extra Chromosome 21 in Cells from Individuals with Down Syndrome Using CRISPR-Cas9 Genome Editing Technology (MIE) 2-First human trials of locally-developed HIV jab begin in South Africa (Yahoo/Telegraph) 3-Mexican Researchers Breakthrough That Could Lead to Complete Elimination of HPV (I24)   CANCER 2:30:55 4-Spanish scientists cure pancreatic cancer in mice in medical breakthrough (Fox) 5-Korean Scientists Reversed Colon Cancer Cells to Normal State (Open Gate Media) 6-Precision conversion of colorectal cancer lung metastases (NIH) 7-Russia unveils first test batches of cancer vaccine (RT) 8-Scientists discover 'levitating' time crystals that you can hold in your hand (Phys.org) 9-New type of magnetism discovered in 2D materials (Phys.org) Clip: Uncles Tremble as Man Invents Vaccine Delivered by Beer (Futurism)   GATES OF THE GODS/SPACE 2:39:29 *Scientists Say Heck, Just Nuke a Killer Asteroid Heading for Earth (Futurism)   EXECUTIVE PRODUCERS 2:47:57 TALENT/TIME 3:00:25 END 3:12:08

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

In this episode, Kyle breaks down how A.W.F.U.L. women are trying to destroy the United States of America. Also, in the Quick Hitters segment, he discusses the killing of Alex Pretti, so-called “journalist” Don Lemon being arrested and indicted for assisting church protestors in Minnesota, the lawsuit alleging that the Christian camp Kanakuk covered up the sexual abuse of children for decades, support for gay people dropping in the US, the Left's wannabe Joe Rogan (Jennifer Welch) saying that “White Evangelical Christianity is a cancer”, the UK aborting itself to death, the NIH announcing it will no longer use tissue from aborted babies for research, the continued spiral of Baylor University away from Christianity, the latest moronic comments from Shane Claiborne, a grizzly murder just a few miles from his house, and much more. Let's get into it… Episode notes and links HERE. Donate to support our mission of equipping men to push back darkness. Learn more about your ad choices. Visit megaphone.fm/adchoices